GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells.
Hansen MS, Søe K, Christensen LL, Fernandez-Guerra P, Hansen NW, Wyatt RA, Martin C, Hardy RS, Andersen TL, Olesen JB, Hartmann B, Rosenkilde MM, Kassem M, Rauch A, Gorvin CM, Frost M.
Hansen MS, et al. Among authors: martin c.
Eur J Endocrinol. 2023 Jan 10;188(1):lvac004. doi: 10.1093/ejendo/lvac004.
Eur J Endocrinol. 2023.
PMID: 36747334